<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D4457A3B-A999-48A7-98C7-14F7D8EB4799"><gtr:id>D4457A3B-A999-48A7-98C7-14F7D8EB4799</gtr:id><gtr:name>Rockefeller Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1F0EDBD-092F-4E9E-AC49-11015F8DF0A8"><gtr:id>D1F0EDBD-092F-4E9E-AC49-11015F8DF0A8</gtr:id><gtr:name>Bocconi University</gtr:name><gtr:address><gtr:line1>Via Roentgen</gtr:line1><gtr:postCode>20136</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83241060-3BAD-499D-BA72-380013794CC6"><gtr:id>83241060-3BAD-499D-BA72-380013794CC6</gtr:id><gtr:name>Abbott</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D4457A3B-A999-48A7-98C7-14F7D8EB4799"><gtr:id>D4457A3B-A999-48A7-98C7-14F7D8EB4799</gtr:id><gtr:name>Rockefeller Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1F0EDBD-092F-4E9E-AC49-11015F8DF0A8"><gtr:id>D1F0EDBD-092F-4E9E-AC49-11015F8DF0A8</gtr:id><gtr:name>Bocconi University</gtr:name><gtr:address><gtr:line1>Via Roentgen</gtr:line1><gtr:postCode>20136</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83241060-3BAD-499D-BA72-380013794CC6"><gtr:id>83241060-3BAD-499D-BA72-380013794CC6</gtr:id><gtr:name>Abbott</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6DC31837-4293-4838-972E-B70F4401FDE0"><gtr:id>6DC31837-4293-4838-972E-B70F4401FDE0</gtr:id><gtr:firstName>Heiner</gtr:firstName><gtr:surname>Grosskurth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A7E4A556-6F0D-4CCF-97A0-3FA60E38CE8C"><gtr:id>A7E4A556-6F0D-4CCF-97A0-3FA60E38CE8C</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>Gilks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4CFEE661-9281-4E12-B253-109123EF97A4"><gtr:id>4CFEE661-9281-4E12-B253-109123EF97A4</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:otherNames>Sarah</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/58B69503-B9E3-43E3-AEB2-82D521E4C95E"><gtr:id>58B69503-B9E3-43E3-AEB2-82D521E4C95E</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:surname>Gibb</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FF7C9766-B80F-4EBF-A578-E69BA282D59A"><gtr:id>FF7C9766-B80F-4EBF-A578-E69BA282D59A</gtr:id><gtr:firstName>Janet</gtr:firstName><gtr:otherNames>Howard</gtr:otherNames><gtr:surname>Darbyshire</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/96D43A36-8970-46E6-8DF4-0FA40E944EFC"><gtr:id>96D43A36-8970-46E6-8DF4-0FA40E944EFC</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Munderi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A6BAEC07-E057-4F0A-933A-BF3E851B5C99"><gtr:id>A6BAEC07-E057-4F0A-933A-BF3E851B5C99</gtr:id><gtr:firstName>Abdel</gtr:firstName><gtr:otherNames>Ghayoum</gtr:otherNames><gtr:surname>Babiker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600344"><gtr:id>E67E5EAB-8DBC-4CC5-B6ED-A12CF8B89DDC</gtr:id><gtr:title>A randomised trial of monitoring practice and treatment interruptions in the management of antiretroviral therapy in HIV</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600344</gtr:grantReference><gtr:abstractText>Most poor countries with many HIV-infected people, such as those in sub-Saharan Africa, are adopting the WHO ?public health approach? for providing anti-HIV (antiretroviral) drugs. This uses simple approaches to treatment that can be delivered by health care workers under supervision of non-specialist clinicians, supported by basic laboratory tests, available. Doctors in specialist hospitals support clinical teams and problem cases are referred to them for expert management. Without this simplified approach, with the severe shortage of doctors and HIV specialists, scaling up anti-HIV drugs provision to meet the needs of HIV-infected people would be impossible.

However, even simple laboratory tests need significant infrastructure (laboratories, reagents, electricity) and trained personnel. Costs of laboratory tests can be as high as costs of the drugs, and are not feasible in large areas of Africa. Finding out whether or not anti-HIV drugs can be given safely and effectively without the intensive routine laboratory testing provided in industrialised countries is of significant relevance to clinical management of HIV-infected people in the developing world. Many anti-HIV drug treatment programmes are struggling to staff and develop laboratory services - if clinical monitoring only (i.e. with no tests) and laboratory monitoring (with tests) have similar clinical outcomes, then emphasis should be given to support and training for quality clinical services, rather than providing laboratory tests. If HIV disease progresses significantly faster when patients receive anti-HIV drugs without regular tests, then provision of anti-HIV drugs must be accompanied by new resources to strengthen and deliver a basic laboratory service.

This proposal describes an extension to an ongoing clinical trial addressing this and other key issues surrounding management of anti-HIV drugs in resource-limited settings. The reason the trial needs an extension is because disease progression is occurring much less frequently than originally anticipated when the trial was started. This is surprising - but is very good news for anti-HIV programmes in Africa and other resource-limited settings, and for trial participants. However, it also means that longer follow-up is needed to meet the trial?s primary objective of evaluating the relative risks and benefits of giving anti-HIV drugs with and without regular laboratory monitoring tests. Given the potentially huge numbers of HIV-infected people in developing countries, for whom the results of this trial will have a direct impact, we believe it is critical to have longer follow-up of DART patients in order to address these questions as originally planned.</gtr:abstractText><gtr:technicalSummary>DART is an open randomised trial evaluating two strategic approaches for ART management in previously untreated symptomatic HIV-infected adults with CD4 cell counts under 200 cells/mm3 initiating ART in three clinical centres in Africa (2 in Uganda and 1 in Zimbabwe). The first strategy compares clinical monitoring only (CMO) with laboratory plus clinical monitoring (LCM) for efficacy (CD4 cell counts) and toxicity (haematology and biochemistry). The second approach compares structured treatment interruptions (STI) (12 weeks on, 12 weeks off ART) with continuous ART in patients who achieve CD4 cell counts over 300 cells/mm3 after 48 weeks on continuous ART. All patients receive triple-drug antiretroviral therapy, with three different regimens being used first-line, one being the standard WHO recommended 2NRTI+NNRTI. The primary endpoint for both comparisons is development of a new WHO stage 4 event (like AIDS) or death, and the trial is designed to demonstrate equivalence between each pair of randomised strategies. 3300 patients were enrolled into the CMO/LCM comparison, and 800 into the STI comparison. Retention and follow-up have been excellent. Substudies including the blinded NORA (Nevirapine OR Abacavir) randomised substudy trial, and a virology substudy are included; high quality DART data are also extremely valuable for addressing numerous epidemiological questions surrounding the optimal use of ART in resource-limited settings. 

Although the approved DART protocol was a 5 calendar year trial (2003-2007), initial MRC funding was for four years in the first instance (because of the application process at the time). Further, over the last year it has become apparent that the rate for the primary endpoint - progression to new WHO stage 4 event or death - is considerably lower than predicted (approx 10% rather than 15% annually). This is surprising - but is very good news for ART programmes in Africa and other resource-limited settings, and for DART participants. However, this lower progression rate reduces the power of the trial. Therefore this proposal describes an extension requested for the DART sites supported by the MRC (MRC Entebbe, MRC CTU and Imperial College) in order to close the funding gap for DART for 2006/2007 and extend the trial for one additional calendar year (2008) to maintain power according to the original trial design. Similar proposals are being developed for partner funders of DART.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2133329</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boehringer Ingelheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Boehringer Ingelheim</gtr:description><gtr:id>B4A9F2D0-1A6D-4C34-ABAC-97DCA8F32D2A</gtr:id><gtr:impact>BI provided first-line drugs for the trial, without which there would have been no publications.</gtr:impact><gtr:outcomeId>3C060AF12CE-1</gtr:outcomeId><gtr:partnerContribution>Provided drugs for the trial</gtr:partnerContribution><gtr:piContribution>The research team ran the trial: BI contributed drugs.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rockefeller Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Rockfeller</gtr:description><gtr:id>DF2BE0E4-56F0-443E-9363-DF64EA4B8183</gtr:id><gtr:impact>Without Rockefeller support for the trial which there would have been no publications.</gtr:impact><gtr:outcomeId>BE181882A4D-1</gtr:outcomeId><gtr:piContribution>The research team ran the trial: Rockefeller supported research costs in 2 of the 4 clinical centres and also supported a full time post throughout the duration of the trial at the MRC Clinical Trials Unit.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Public Health and Policy</gtr:department><gtr:description>University of Liverpool</gtr:description><gtr:id>E64CBB4F-CD76-4551-81A7-D1FC6E1477E7</gtr:id><gtr:impact>Cost effectiveness analysis - oral presentation at the International AIDS Society conference, Cape Town July 2009
Publication in PLos One</gtr:impact><gtr:outcomeId>32CF879630B-1</gtr:outcomeId><gtr:partnerContribution>Supported health economist</gtr:partnerContribution><gtr:piContribution>Research team ran the trial providing underlying data for cost effectiveness analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GlaxoSmithKline</gtr:description><gtr:id>0FB632A3-CF65-408C-8C96-0E8421267446</gtr:id><gtr:impact>GSK provided first-line drugs for the trial, without which there would have been no publications. They also provided specific funding for PMID 16791013, 19938977, 20136661</gtr:impact><gtr:outcomeId>76A671233E7-1</gtr:outcomeId><gtr:partnerContribution>GSK provided drugs for the trial.</gtr:partnerContribution><gtr:piContribution>The research team ran the trial: GSK contributed drugs and funding for specific substudies.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bocconi University</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Health Economics</gtr:department><gtr:description>Bucconi University, Milan, Italy</gtr:description><gtr:id>9C6D800E-AF79-4398-AA28-3467919B6CFB</gtr:id><gtr:impact>Final cost-effectiveness paper about to be submitted to NEJM. This collaboration is multi-disciplinary involving health economists from Bucconi, and statisticians and clinicians from the DART team.</gtr:impact><gtr:outcomeId>YAh55x7L3rx-1</gtr:outcomeId><gtr:partnerContribution>Supported health economist who moved from University of Liverpool during 2010. Will provide a Research Assistant to help write up primary costing papers from the health economics analysis during 2011.</gtr:partnerContribution><gtr:piContribution>Collected data to inform the cost-effectiveness analysis. Have commented extensively on draft manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Clinical Pharmacology</gtr:department><gtr:description>University of Liverpool - PK</gtr:description><gtr:id>DCB9322A-3A55-40DB-BFD8-D343B84FFCB0</gtr:id><gtr:impact>Manuscript under review with AAC so not listed, but oral presentation by Ugandan co-PI at the 9th International Congress on HIV and Drug Therapy in HIV Infection, November 2008.</gtr:impact><gtr:outcomeId>70C109C3488-1</gtr:outcomeId><gtr:partnerContribution>In kind contribution running drug assays for pharmacokinetic studies</gtr:partnerContribution><gtr:piContribution>Research team ran the trial; wrote substudy protocol, recruited trial participants into additional PK substudies, and jointly drafted manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of the UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>DFID</gtr:description><gtr:id>0817302E-D221-4801-AEBB-8935D0C8DCD6</gtr:id><gtr:impact>DART trial: Without DFID support there would have been no publications, and no cost-effectiveness analysis. DFID also funded the Policy Briefing document, a four page glossy summarising the trial results for policymakers and governments.
ARROW trial (including winning 2014 BMJ Paper of the year which was submitted by DfID)</gtr:impact><gtr:outcomeId>1EEDADF2030-1</gtr:outcomeId><gtr:partnerContribution>DART TRial: DFID contributed funding for additional drugs and the cost-effectiveness evaluation
ARROW Trial: co-funding, Young Lives Project; economic substudies
LAblite Project is funded by DfID</gtr:partnerContribution><gtr:piContribution>Dfid have co-funded a number of trials (and substudies) and projects we have coordinated including DART, ARROW, REALITY trials and Lablite project</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Abbott</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Abbott</gtr:description><gtr:id>DF7F0923-E7D7-448B-A4EE-C2AB94092D7C</gtr:id><gtr:impact>Abbott provided second-line drugs for the trial, without drugs there would have been no publications.</gtr:impact><gtr:outcomeId>AB6CF9C394A-1</gtr:outcomeId><gtr:partnerContribution>Provided second-line drugs for the trial and some funding for second-line substudies.</gtr:partnerContribution><gtr:piContribution>The research team ran the trial: Abbott contributed drugs and funding for specific substudies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Gilead Sciences</gtr:description><gtr:id>F49C1F58-CB98-4EB6-8C90-5CA2A1C7FB04</gtr:id><gtr:impact>Gilead provided first-line drugs for the trial, without which there would have been no publications. They also provided specific funding for PMID 18444867, 18839777 and for the current PENTA 17 (SMILE) elvitegravir trial</gtr:impact><gtr:outcomeId>7E6F8B128A4-1</gtr:outcomeId><gtr:partnerContribution>Provided drugs for the trial</gtr:partnerContribution><gtr:piContribution>The research team ran the trial: Gilead contributed drugs and funding for specific substudies.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>DART Film 2 - Policy Recommendations</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>E842856D-3098-4217-9A95-7FD87B0332AD</gtr:id><gtr:impact>A short 10 minute film outlining policy recommendations arising from DART was produced and uploaded to the MRC hosted youtube channel. It was advertised via link from partner organisations and from news stories, and from other sites such as EfA and i-base. It is featured on Facebook and twitter.

Alongside the 2 minute film uploaded to youtube alongside results of the trial in 2009 this marks a significant presence online. With wide search terms and raising popularity the films are now suggested viewing to youtube users (over 2000 views of the peices combined).</gtr:impact><gtr:outcomeId>YrwgKWvzGUg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>8F781CF4-A73B-43B0-B4C8-B47B7C1AF7D0</gtr:id><gtr:impact>The DART film and information about the trial were featured in a British Science Festival event &amp;quot;the Truth about Trials&amp;quot;, led by MRC and Birmingham University. Press papers produced for the event and distriubuted widely.

The event led to the request for an interview with the Naked Scientists which is published online as a podcast and widely distributed through partner websites, facebook, twitter and the Naked Scientists.</gtr:impact><gtr:outcomeId>Fwkov2u6yap</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DART Film (2)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>66577F78-8037-496F-AA0B-B2C5253BE29D</gtr:id><gtr:impact>The DART film has continued to be used since reporting in 2009. It has been shown on BBC World Internationally and on the Research Channel in the United States. It has also been featured on TV in Uganda, Botswana, Kenya, Malawi, Zambia, Tanzania, Nigeria. It will be particularly featured over World AIDS Day (1st December 2010).

The film is also used widely as an educational resource for secondary / high schools in UK and the US. It is featured in a number of teaching programmes at Medical School level (Imperial and UCL).

In addition it has been used as a way of engageing with policy makers, academics and medical practitioners in International Forums such as CROI, IAS, World Aids and other international meetings. Trial sites are provided with copies for their own promotional and advicasy purposes.

The film is a well regarded and powerful tool for dissemination and engagement. This has helped recognition of the trials relevance and important results. It has also stimulated debate about the use of such media in the process of using research to inform public opinion and policy.</gtr:impact><gtr:outcomeId>btjDotjhDw6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DART participants meetings</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>91ED7D44-79E5-4312-A1C0-54C4CC044F69</gtr:id><gtr:impact>Each DART centre held a participants day/celebration after the results were presented internationally in July 2009 to feedback the results of the trial to participants. Presentations were done by junior doctors. These participants days were also held annually during the trial.

Participants were very appreciative of being told results early in the dissemination process. Throughout the trial, regular meetings with participants enabled researchers to become aware of concerns and issues before these developed into major problems.</gtr:impact><gtr:outcomeId>134BB2E5361</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio, Television and Magazine Interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>389E3642-0AC7-4642-BA3C-B9E93494D2CD</gtr:id><gtr:impact>A significant number of interviews have been given by the trial team in response to requests from the media. These include over 9 radio interviews / podcasts, over 10 magazine or newspaper articles and at least 6 television interviews worldwide.

High impact activities by the trial investigators result in wider interest in the trial results accross academic, non-academic communities, including policymakers and the general public.</gtr:impact><gtr:outcomeId>Jn34isWS2WB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DART policy brief</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>E6B2DEBE-772E-446C-A2E8-86BFC687AE30</gtr:id><gtr:impact>An A3 (folded, so 4 A4 pages) glossy policy briefing document has been produced summarising the key trial findings and aimed at health policymakers.

The policy brief was launched by DFID on 9 December 2009, the day the primary manuscript was published, so not enough time to identify impact yet.</gtr:impact><gtr:outcomeId>8A6F082079B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Debating Matters</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>117C3D5B-7D12-42A0-B836-C16710921439</gtr:id><gtr:impact>DART was used in a debating topic in the National Debating Matters annual debating competition. PI Diana Gibb acted as judge in a heat and the finals.

Wide dissemination of the DART trial and issues around performing clinical research in Africa accross secondary pupils in the UK.</gtr:impact><gtr:outcomeId>gAt8X5Mr1CD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DART presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D7FB91F4-0A43-4C2B-BF0C-E241F8C2AF13</gtr:id><gtr:impact>Presentation of main DART results to health professionals at seminars, national meetings etc, has occurred in Uganda, Zimbabwe and the UK

DART was awarded best research in 2009 at the Zimbabwe Institute of Continued Health Education annual meeting, and a junior DART doctor was awarded best Presenter.</gtr:impact><gtr:outcomeId>74582036C3B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Online Presence</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>B03A66EB-0314-4300-A92F-842296C2B2FE</gtr:id><gtr:impact>The DART website is widely used and referred - a google link search completed on 24 November 2010 confirmed 5150 infomedia websites which provide a link to the website.

DART is a widely known trial and information about the trial is used internationally.</gtr:impact><gtr:outcomeId>eduLTqvHcAA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancet Paper of the Year</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>41996E94-B052-4057-BC66-E96780AF0981</gtr:id><gtr:impact>The DART main results paper was nominated for the Lancet Paper of the Year - a competition which considers entrants not just from Lancet publications but all journals worldwide. In a public vote, the paper was voted runner-up.

This gave the paper huge exposure and was considered a significant accolade. It also resulted in a number of press releases.</gtr:impact><gtr:outcomeId>eTHprhJMp5a</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DART film (1)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>E56E0911-6814-48DE-AF6A-5C51401A7CF6</gtr:id><gtr:impact>A film describing the DART trial, narrated by a trial participant, was produced - shown on BBC World as a 20 min short, and produced on DVD as a longer film with chapters and is being widely distributed both to disseminate trial results and also for education about research, why it is done, what it means.

During 2010-11, the film has had colour correction work to bring it to broadcast standard. It has been re-packaged as a DVD containg two versions of the film (26.5 minutes and 52.5 minutes) and a number of discrete chapters which can be embedded to websites or used in presentations. These DVDs are available in both PAL (African and European format, broadly speaking) and NTSC (US format). 

The DART film has been provided on broadcast quality tape and shown on:

BBC World (International, repeatedly shown over a period of 7 days, late 2009)
Botswana TV (date to be confirmed, tape provided November 2010)
Kingdom TV, Nigeria (date to be confirmed, tape provided November 2010)
Kenya Broadcasting Corporation (date to be confirmed, tape provided November 2010)
Uganda Broadcasting Corporation (on several occasions since November 2009)
Ugandan Wavah Broadcasting Service (on several occasions since early 2009)
United States of America 'The Research Channel' (September 2010)
University of Washington (United States, September 2010, and podcasting)
Television Malawi (date to be confirmed, tape provided November 2010)
Zambia Broadcasting Corporation (date to be confirmed, tape provided November 2010)

The film has also sparked debate on various blogs.

The film has been extremely well received and noted in public as a highly innovative way to disseminate trial information. 

Tom Gibb, who made the film was nominated and shortlisted for the British Medical Journal Health Communicator of the Year Award, for his work on the DART films. Inevitably this led to further exposure for the film and DART results, but it was also a deserved recognition of the success of the films.</gtr:impact><gtr:outcomeId>300EC780477</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>29983</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Alexander Fleming Dissemination Scheme</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>38F4B918-3AFD-44E0-93B3-5D6F12D78D8B</gtr:id><gtr:outcomeId>Ur6Ce2woUWY0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1896304</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>DFID</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:id>5FFB7013-1831-46B1-B2E5-41212D439929</gtr:id><gtr:outcomeId>tUaMzres5Hu0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO 2010 Guidelines Committees</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6ECED6F3-95F4-448B-BD26-05493E659933</gtr:id><gtr:impact>WHO guidelines set the standard for HIV treatment in resource-limited settings</gtr:impact><gtr:outcomeId>2516333D89E</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Uganda/Zimbabwe Ministries of Health</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>BD892422-A205-42A1-AB5A-FC3E51E5FBB5</gtr:id><gtr:impact>Contribution from DART co-PIs has shaped national HIV/AIDS policy.</gtr:impact><gtr:outcomeId>4040FFD40CB</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO 2006 guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Antiretroviral therapy for HIV Infection in Adults and Adolescents: recommendations for a public health approach 2006</gtr:guidelineTitle><gtr:id>4BEE9137-6CD7-4201-9CCD-36688BDD9838</gtr:id><gtr:impact>In 2006 guidelines, DART was referenced in three areas (primary randomisation was still ongoing): development of anaemia on zidovudine-based regimens, virological response to 3NRTI first-line, and high incidence of early mortality on ART</gtr:impact><gtr:outcomeId>6603DBB7C1E</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.who.int/hiv/pub/arv/adult/en/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>4 RANDOMISATIONS 1) monitoring for efficacy &amp;amp; toxicity in African adults on antiretroviral therapy 2) antiretroviral interruptions 3 &amp;amp; 4) second line therapy strategies</gtr:description><gtr:id>A927AA7D-D658-414C-BBA1-7F8397A84B62</gtr:id><gtr:impact>Impact on management of ART roll out in Africa, influenced WHO guidelines 2010 and 2013.</gtr:impact><gtr:outcomeId>pbnJDg9AT98</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Development of AntiRetroviral Therapy in Africa (DART)</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN13968779</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5BBDC1A9-8EC2-40DA-877E-D70193907BD4</gtr:id><gtr:title>Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_14873_23_22972859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>889690C6-AFB8-4F29-87B1-B55035F56AE3</gtr:id><gtr:title>Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3417d4ce8ff7e6e00ba6e34e64293c2b"><gtr:id>3417d4ce8ff7e6e00ba6e34e64293c2b</gtr:id><gtr:otherNames>DART Virology Group and Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>631E8F079ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56D0A9DB-72E5-4C7A-A2A5-7A0E09BF4F9D</gtr:id><gtr:title>Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>mg6c3cfGKaX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12382FE1-6C07-441C-B413-7F7C10880302</gtr:id><gtr:title>Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5C162D8CBF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E7FF662-89C6-452E-A58A-2FF515552FD5</gtr:id><gtr:title>The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a33fa6051a8ca7b043ffc187a316bff"><gtr:id>4a33fa6051a8ca7b043ffc187a316bff</gtr:id><gtr:otherNames>Ford D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>56e016e029cfb2.62670338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F52D9D0-8CF1-4F29-8797-DF0BA6104EF1</gtr:id><gtr:title>Clustering based on adherence data.</gtr:title><gtr:parentPublicationTitle>Epidemiologic perspectives &amp; innovations : EP+I</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/207f4372d9394a7f2f77d3925ca02563"><gtr:id>207f4372d9394a7f2f77d3925ca02563</gtr:id><gtr:otherNames>Kiwuwa-Muyingo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-5573</gtr:issn><gtr:outcomeId>pm_14873_23_21385451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BF601FA-8354-45A3-BB26-334DC546366B</gtr:id><gtr:title>The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>5a2fd5db9ea739.55372932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9022D682-854F-4926-B455-24EC53E2931D</gtr:id><gtr:title>Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36c594481c9e5162bca5d1edaf25ac0"><gtr:id>a36c594481c9e5162bca5d1edaf25ac0</gtr:id><gtr:otherNames>Kityo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>fFgbNq46NxN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>597DACF1-9529-40B5-B26E-97DE20048B77</gtr:id><gtr:title>Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a8bde31d95ec586098b2322368ff463"><gtr:id>5a8bde31d95ec586098b2322368ff463</gtr:id><gtr:otherNames>Ndembi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>013B689A720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1382E383-E174-4382-AC44-23DC809107DE</gtr:id><gtr:title>The charms and challenges of antiretroviral therapy in Uganda: the DART experience.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0762bb899ef58b61c34366d087672b9a"><gtr:id>0762bb899ef58b61c34366d087672b9a</gtr:id><gtr:otherNames>Nyanzi-Wakholi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>MuYr76qnUgS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20B6AAE4-3B0C-4C6B-81FE-ACB906DF26EF</gtr:id><gtr:title>Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86639c545eecdfa7889a1cca13b5c01e"><gtr:id>86639c545eecdfa7889a1cca13b5c01e</gtr:id><gtr:otherNames>Gomo ZA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>doi_55faa1aa19921254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80805C1B-AC37-4B10-9A25-18C7BE5512E2</gtr:id><gtr:title>Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7da11026bd77b80de9adabc4b8b7c17f"><gtr:id>7da11026bd77b80de9adabc4b8b7c17f</gtr:id><gtr:otherNames>Sutherland KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e016df99cc60.47741375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>250566FD-2180-43FC-8AA7-81DC33164703</gtr:id><gtr:title>The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/207f4372d9394a7f2f77d3925ca02563"><gtr:id>207f4372d9394a7f2f77d3925ca02563</gtr:id><gtr:otherNames>Kiwuwa-Muyingo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>pm_14873_23_22463596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5572B23-B780-4EC5-B7F1-031DA3BA13C7</gtr:id><gtr:title>Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7f5f4c8349da86b35e3575dc9bd508e"><gtr:id>c7f5f4c8349da86b35e3575dc9bd508e</gtr:id><gtr:otherNames>Medina Lara A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14873_23_22545079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABBE68AE-89AE-41AC-8023-DFF111D58414</gtr:id><gtr:title>Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af41ba5a001caff9cfc7754a2e495376"><gtr:id>af41ba5a001caff9cfc7754a2e495376</gtr:id><gtr:otherNames>Dart Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>32C777C8B57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58E2A388-CB00-4A06-91A7-5126E7D1BEA6</gtr:id><gtr:title>The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0762bb899ef58b61c34366d087672b9a"><gtr:id>0762bb899ef58b61c34366d087672b9a</gtr:id><gtr:otherNames>Nyanzi-Wakholi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>KZAr7xxP3EM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DEA3375-9061-4DA0-84CA-88F4030C11A6</gtr:id><gtr:title>CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells &amp;lt;200 Cell/?L: The DART Trial STI Substudy.</gtr:title><gtr:parentPublicationTitle>AIDS research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c4ac075a6de4679b80ef146ceae513"><gtr:id>40c4ac075a6de4679b80ef146ceae513</gtr:id><gtr:otherNames>Serwanga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-1240</gtr:issn><gtr:outcomeId>TCuLZh1BtNe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBB93616-1784-4CBB-9EE8-8C8A73DA98C0</gtr:id><gtr:title>Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14356e9699c962c762a4c6e584b266bc"><gtr:id>14356e9699c962c762a4c6e584b266bc</gtr:id><gtr:otherNames>Gibb DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_14873_23_22615543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>137FF976-3B4E-4CD7-989B-2E3B90E71865</gtr:id><gtr:title>Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts &amp;lt; 200 cells/microl.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/300bcd2c5353d921955a498aa2888782"><gtr:id>300bcd2c5353d921955a498aa2888782</gtr:id><gtr:otherNames>DART Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>6EB68E2E897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17E1F172-AF26-4CDC-A5E0-C2F98885CB91</gtr:id><gtr:title>Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/051cf62d6d905f0304eb0c4d1af8ba2e"><gtr:id>051cf62d6d905f0304eb0c4d1af8ba2e</gtr:id><gtr:otherNames>Lyagoba F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>EiaZVUjLJQY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFA9C9EC-29BB-4081-BEA8-9935E350DBC0</gtr:id><gtr:title>Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>YWHzJCstCdD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6223984C-05EA-423D-8945-0E079EB8AB0C</gtr:id><gtr:title>High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56e016e16fc500.44531983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A43173BD-9E10-4008-BC9A-1774C8D48E52</gtr:id><gtr:title>Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f76496409ebd723eb37f62919a49eeb"><gtr:id>4f76496409ebd723eb37f62919a49eeb</gtr:id><gtr:otherNames>Gilks CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_14873_23_22814125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E64B14DD-9EEF-43CB-81E4-E63D45408BA3</gtr:id><gtr:title>Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1132c254e977729416cdedf9f3f7428"><gtr:id>c1132c254e977729416cdedf9f3f7428</gtr:id><gtr:otherNames>Muyingo SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>F2F1EA77D12</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47D7D8AD-CC8B-45EB-8CF6-F498BDBB19EF</gtr:id><gtr:title>CYP2B6 c.983T&amp;gt;C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>doi_55faa1aa197ebf07</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68D5BB84-637A-4734-A987-1E4E9D2EEA82</gtr:id><gtr:title>Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7da11026bd77b80de9adabc4b8b7c17f"><gtr:id>7da11026bd77b80de9adabc4b8b7c17f</gtr:id><gtr:otherNames>Sutherland KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>56e016e04d0961.49667376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>780971AC-DBC0-4145-B94A-36F68F8B17BF</gtr:id><gtr:title>Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/207f4372d9394a7f2f77d3925ca02563"><gtr:id>207f4372d9394a7f2f77d3925ca02563</gtr:id><gtr:otherNames>Kiwuwa-Muyingo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55faa1aa198885aa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66874CBF-7E38-45C1-BBD2-E4626076078D</gtr:id><gtr:title>Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3b7c33fb7f28422e6e5f4f9e4e18c6f"><gtr:id>f3b7c33fb7f28422e6e5f4f9e4e18c6f</gtr:id><gtr:otherNames>Parikh SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55faa1aa199b9bc2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8AFFA33-BE8B-47E7-9135-5F96A8838F9C</gtr:id><gtr:title>Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3351d89d5f121bef6fc5cb4126499a9b"><gtr:id>3351d89d5f121bef6fc5cb4126499a9b</gtr:id><gtr:otherNames>Goodall RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56e016e107a146.90526800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBFE26DE-EE7D-4FB0-BC4E-0833BEBCBFA7</gtr:id><gtr:title>Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a115fb22ae8b5eb1d761afe50087d24"><gtr:id>9a115fb22ae8b5eb1d761afe50087d24</gtr:id><gtr:otherNames>McCormick AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>GMvS4fNitYN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA6105E0-F897-4BDF-A047-5D20128B4B86</gtr:id><gtr:title>Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c4ae4cbda123b1042157359c2b7125"><gtr:id>72c4ae4cbda123b1042157359c2b7125</gtr:id><gtr:otherNames>Lara AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>1D98453A482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB61AF83-1D8E-4B4D-A528-05A2EE234F40</gtr:id><gtr:title>Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/204b3fba8c82b0d72f21535fc6b103d3"><gtr:id>204b3fba8c82b0d72f21535fc6b103d3</gtr:id><gtr:otherNames>Ssali F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>3729FFF45BE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86D90AD9-359D-4196-AFEC-ECAE7D992184</gtr:id><gtr:title>High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36c594481c9e5162bca5d1edaf25ac0"><gtr:id>a36c594481c9e5162bca5d1edaf25ac0</gtr:id><gtr:otherNames>Kityo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e14ae14a902a7a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A59F887C-1669-4CCF-ABCB-8F09A8E8E138</gtr:id><gtr:title>Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>Wgtjw5Qh75d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88221D38-79A9-46FE-B177-8BECEC4BD1EE</gtr:id><gtr:title>Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/207f4372d9394a7f2f77d3925ca02563"><gtr:id>207f4372d9394a7f2f77d3925ca02563</gtr:id><gtr:otherNames>Kiwuwa-Muyingo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>56e01af196f317.83025206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>718A932A-B9B2-4CE5-807C-CBA0310202D7</gtr:id><gtr:title>Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>iNkZCmhLpN2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54022CD0-93A4-4E16-88CC-84FE7AC47CF8</gtr:id><gtr:title>Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96888be17bf947367e44907c170ce926"><gtr:id>96888be17bf947367e44907c170ce926</gtr:id><gtr:otherNames>Kikaire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>CC1F2423961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0B4709E-A472-48EB-BDE5-8F0F472C522F</gtr:id><gtr:title>HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db9bd2e5b713d322ea56e628dd375b9b"><gtr:id>db9bd2e5b713d322ea56e628dd375b9b</gtr:id><gtr:otherNames>Jaganath D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>5464a7e97e5453.75850653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>418485C2-67E0-4BF9-B3D1-A1EDE843E366</gtr:id><gtr:title>Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f409e6effa963165e88c95c6b2a649eb"><gtr:id>f409e6effa963165e88c95c6b2a649eb</gtr:id><gtr:otherNames>Reid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>89C1273F660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43A81DF1-D2E2-4291-90A1-D81DE0740D07</gtr:id><gtr:title>Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5a353ad6bff813.03720451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>668DF1F6-948E-4F59-98B9-DFB837C5A8DA</gtr:id><gtr:title>Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/300bcd2c5353d921955a498aa2888782"><gtr:id>300bcd2c5353d921955a498aa2888782</gtr:id><gtr:otherNames>DART Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>LmY3tZrPJHP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFD4BD42-C6B1-4AFA-AFE9-3450C5F7D033</gtr:id><gtr:title>A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f76496409ebd723eb37f62919a49eeb"><gtr:id>4f76496409ebd723eb37f62919a49eeb</gtr:id><gtr:otherNames>Gilks CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14873_23_23437399</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600344</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>E4AF608A-CDB6-4CE6-AA10-95B3E043E22F</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.1  Organisation and delivery of services</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>